• Lyell Immunopharma presented updated Phase 1/2 safety results for ronde-cel in relapsed or refractory large B-cell lymphoma at EHA 2026.
• Data showed a manageable safety profile with no severe cytokine release syndrome, supporting potential outpatient use.
• Separate translational findings, also presented at EHA, linked durable responses to the product’s manufacturing approach and dual CD19/CD20 targeting.
• The pivotal single-arm PiNACLE trial in third-line and later patients is set to deliver an updated dataset in 2H 2026.
• Lyell expects a pivotal readout in mid-2027, targeting a BLA submission in 2H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606121245PRIMZONEFULLFEED9745993) on June 12, 2026, and is solely responsible for the information contained therein.